Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2010 Effects of SNDX-275 on expression of biomarkers in breast cancer Syndax Pharmaceuticals PI
2. 2010 Molecular Profiling in Early Breast Cancer GlaxoSmithKline Pharmaceuticals PI
3. 2009 An exploratory study to evaluate the biological activity of R1507 in women with operable breast cancer Roche Pharmaceuticals PI
4. 2008 A phase I pharmacodynamic concentration response assessment of KU-0059436 administered to intermediate and high risk breast cancer patients scheduled for elective surgery KuDOS PI
5. 2008 The clinical effectiveness and cost-effectiveness of different surveillance mammography regimes after the treatment of primary breast cancer HTA NHS R&D Research Grant PI
6. 2008 Identification and functional validation of additional therapeutic targets in HER2 amplified breast cancers Breakthrough Breast Cancer PI
7. 2008 Margaret B Reekie Research Fellowship Miss M B Reekie’s Charitable Trust PI
8. 2008 A study to determine the activity of poly (ADP-Ribose) polymerase (PARP) in different breast tumour types KuDOS PI
9. 2007 Breakthrough Breast Cancer Research Unit at University of Edinburgh Breakthrough Breast Cancer PI
10. 2007 Programme grant – experimental cancer medicine: Edinburgh Cancer Research Centre Cancer Research UK PI
11. 2006 Comparison of the Anti-tumour Effects and Tolerability of Faslodex Plus Arimidex with Faslodex alone, or Arimidex Alone in Postmenopausal Women Prior to Surgery for Primary Breast Cancer AstraZeneca UK Ltd PI
12. 2006 A Randomised Trial to Determine the Short-term Biological Effects of Zoledronate and Letrozole on Invasive Breast Cancer Pfizer PI
13. 2005 A Study to Evaluate the Biological Effects of RAD001 (5mg) on Invasive Breast Cancer Novartis Pharma PI
14. 2005 PRIME 2 trial: randomised trial of post-operative breast irradiation in low risk older patients Chief Scientists Office PI
15. 2005 Molecular Analysis of Breast Cancer National Cancer Institute, United States of America PI
16. 2005 Endocrine Therapy of Breast Cancer Department of Defence, US Army Grants, United States of America PI
17. 2005 A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase I Study to Assess the Biological Activity of AZD0530 in Patients with Early Breast Cancer AstraZeneca UK Ltd PI
18. 2005 A Study to Investigate the Effectiveness of Trilostane as a Hormonal Treatment for Breast Cancer Bioenvision Ltd PI
19. 2005 SUPREMO trial assessing the role of postmastectomy radiotherapy in intermediate risk breast cancer Medical Research Council PI
20. 2003 Effects of exemestane and cox-2 inhibition on oestrogen receptor positive ductal carcinoma in situ Pharmacia Ltd PI
21. 2003 A study to compare the effect of different aromatase inhibitors on bone and lipid metabolism and clotting in postmenopausal women with oestrogen receptor positive breast cancer Pharmacia Ltd PI
22. 2003 TELEMAM Trial for the evaluation of telemedicine in multidisciplinary management of breast cancer Dept of Health Research and Development PI
23. 2003 SCH-57068 (EM-652): A non-steroidal selective oestrogen receptor modulator (SERM) for use as an improved HRT or for hormonal treatment of breast cancer Centre de Recherche du CHUL, Canada PI
24. 2003 An investigation into quality of life and tolerability: anastrozole versus letrozole Novartis Pharma PI
25. 2003 Fulvestrant versus tamoxifen in premenopausal women with breast cancer AstraZeneca UK Ltd PI
26. 2003 A Study to Assess the Variability of Src Kinase in Primary Breast Cancer Tumours AstraZeneca UK Ltd PI
27. 2002 LETMA 2 Study Novartis Pharma AG PI
28. 2002 A study to compare the effects of fulvestrant and tamoxifen in premenopausal women with oestrogen receptor positive breast cancer AstraZeneca Pharma UK PI
29. 2002 A study to compare the effects of letrozole and anastrozole in postmenopausal women with oestrogen receptor positive breast cancer Novartis Pharma PI
30. 2001 IMPACT – Immediate Preoperative Arimidex Alone or Combined with Tamoxifen NA PI
31. 2000 Study of preoperative neoadjuvant tamoxifen or anastrozole alone or in combination AstraZeneca Pharmaceuticals PI
32. 1999 A study of the effects of letrozole on the mRNA for the enzyme aromatase Novartis Pharma AG PI
33. 1999 Trial of sentinel node biopsy in breast cancer: a randomised trial of sentinel node guided treatment against conventional axillary management in early breast cancer Medical Research Council PI
34. 1999 Neo-adjuvant letrozole versus tamoxifen therapy for large operable and locally advanced oestrogen receptor positive breast cancer Novartis Pharma AG PI
35. 1998 A study of the Biofield test in a population of women with suspicious breast lesions. Biofield Corporation PI
36. 1998 Exemestane as neoadjuvant treatment for locally advanced breast cancer: focus on clinical and biological endpoint Pharmacia & Upjohn PI
37. 1998 Study of the new pure antioestrogen Faslodex in breast cancer Zeneca Pharmaceuticals PI
38. 1997 Study of the effects of letrozole on biological factors in human breast cancer Novartis Pharma AG PI
39. 1997 The PRIME (Postoperative Radiotherapy in Minimum-risk Elderly) breast cancer trial Dept of Health Technology Assessment PI
40. 1997 Study of the short term effects of idoxifene on biological characteristics of human breast cancer SmithKline Beecham PI
41. 1997 Angiogenesis: its role in breast cancer and effect of tamoxifen treatment Royal College of Surgeons of England PI
42. 1996 Angiogenesis: its role in breast cancer and effect of tamoxifen treatment Royal College of Surgeons of England PI
43. 1996 National multi-centre study of magnetic resonance imaging (MRI) screening in women at genetic risk of breast canc Medical Research Council PI
44. 1996 Study of the effects of arimidex on uptake and synthesis of oestrogens by human breast cancer Zeneca Pharmaceuticals PI
45. 1996 Further study of the effect of the aromatase inhibitor CGS 20267 in breast cancer Ciba Geigy Pharmaceuticals PI
46. 1995 The in vivo uptake and synthesis of oestrogens by human breast cancer: the effect of the aromatase inhibitor CGS 20267 Ciba Geigy Pharmaceuticals PI
47. 1994 The mapping and characterisation of a putative suppressor gene on chromosome 17p13.3 implicated in human breast cancer Chief Scientists Office, Home and Health Department, Scottish Office PI
48. 1991 A study of transforming growth factor beta in breast cancers treated with tamoxifen Scottish Hospital Endowments Research Trust PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.